These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 31385283)

  • 1. Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases.
    Moran K; Null K; Huang Z; Lissoos T; Kane S
    Adv Ther; 2019 Sep; 36(9):2260-2272. PubMed ID: 31385283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
    Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
    Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonadherence to Biologic Therapies in Inflammatory Bowel Disease.
    Wentworth BJ; Buerlein RCD; Tuskey AG; Overby MA; Smolkin ME; Behm BW
    Inflamm Bowel Dis; 2018 Aug; 24(9):2053-2061. PubMed ID: 29668917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse Events and Compliance Among Inflammatory Bowel Disease Patients Treated With Home- vs Office-Based Biologic Infusions.
    Schmoyer CJ; Sun K; Zack J; Kumar P; Shivashankar R
    Inflamm Bowel Dis; 2024 Sep; 30(9):1529-1535. PubMed ID: 37819840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADHERENCE AND PERSISTENCE TO TREATMENT WITH INFLIXIMAB: ANALYSIS OF A PATIENT SUPPORT PROGRAM COHORT IN BRAZIL.
    Branco ABXC; Argolo W; Santos N; Hernandez G; Kakehasi A; Sobrado CW; Melsheimer R
    Arq Gastroenterol; 2024; 61():e23149. PubMed ID: 38775584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
    Jung YS; Han M; Park S; Cheon JH
    Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases.
    Harnett J; Curtis JR; Gerber R; Gruben D; Koenig A
    Clin Ther; 2016 Jun; 38(6):1451-1463. PubMed ID: 27112534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
    J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease.
    Null K; Kumar V; Lissoos T; Luo M
    J Med Econ; 2018 Nov; 21(11):1102-1109. PubMed ID: 30101633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing adherence and persistence across 6 chronic medication classes.
    Yeaw J; Benner JS; Walt JG; Sian S; Smith DB
    J Manag Care Pharm; 2009; 15(9):728-40. PubMed ID: 19954264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician.
    Chang S; Hudesman D
    Curr Gastroenterol Rep; 2020 Jan; 22(2):7. PubMed ID: 32002688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis.
    Li P; Blum MA; Von Feldt J; Hennessy S; Doshi JA
    Value Health; 2010; 13(6):805-12. PubMed ID: 21054657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database.
    Mease PJ; Young P; Gruben D; Fallon L; Germino R; Kavanaugh A
    Adv Ther; 2022 Jun; 39(6):2932-2945. PubMed ID: 35482248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to "Comment on Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases".
    Moran K; Null K; Huang Z; Lissoos T; Kane S
    Adv Ther; 2020 Apr; 37(4):1697-1700. PubMed ID: 32173794
    [No Abstract]   [Full Text] [Related]  

  • 16. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
    Dulai PS; Osterman MT; Lasch K; Cao C; Riaz F; Sandborn WJ
    Dig Dis Sci; 2019 Sep; 64(9):2478-2488. PubMed ID: 30923985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing adherence to infusion-based biologic therapies in patients with inflammatory bowel disease.
    Haar GS; Vasudevan A; Curtain CM; van Langenberg DR
    Res Social Adm Pharm; 2021 Aug; 17(8):1420-1425. PubMed ID: 33129684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Analysis of 3-Year Persistence With Vedolizumab Compared With Antibodies Against Tumor Necrosis Factor-Alpha in Patients With Inflammatory Bowel Disease in Germany: Retrospective Analysis of a Large Prescription Database.
    Helwig U; Kostev K; Schmidt C
    J Clin Gastroenterol; 2021 Jan; 55(1):e1-e7. PubMed ID: 32011403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.
    Giese-Kim N; Wu M; Dehghan M; Sceats LA; Park KT
    Am J Gastroenterol; 2020 Oct; 115(10):1698-1706. PubMed ID: 32701731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.